We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+35.04%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$181M
Cap. Flow
-$1.32M
Cap. Flow %
-0.07%
Top 10 Hldgs %
41.59%
Holding
123
New
29
Increased
30
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$28.3M
2
ANAB icon
AnaptysBio
ANAB
+$26.6M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$20.4M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$19.6M
5
ERAS icon
Erasca
ERAS
+$17.1M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$58.6M
2
WVE icon
Wave Life Sciences
WVE
+$16.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$14.8M
4
ACLX
Arcellx
ACLX
+$14.2M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.51%
2 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADGM
101
Adagio Medical Holdings
ADGM
$11.8M
$92K ﹤0.01%
80,000
– –
RCKTW icon
102
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$1.18K ﹤0.01%
75,000
– –
ABUS icon
103
CALL
Arbutus Biopharma
ABUS
$901M
– –
-521,900
Closed -$2.51M
AMGN icon
104
CALL
Amgen
AMGN
$198B
– –
-135,000
Closed -$44.2M
AMGN icon
105
Amgen
AMGN
$198B
– –
-10,000
Closed -$3.27M
AVDL
106
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-250,000
Closed -$5.39M
FBRX icon
107
CALL
Forte Biosciences
FBRX
$1B
– –
-22,400
Closed -$611K
GERN icon
108
Geron
GERN
$924M
– –
-1,500,000
Closed -$1.98M
IBB icon
109
CALL
iShares Biotechnology ETF
IBB
$9.23B
– –
-400,000
Closed -$67.5M
MRSN
110
DELISTED
Mersana Therapeutics
MRSN
– –
-100,000
Closed -$2.89M
QURE icon
111
uniQure
QURE
$2.77B
– –
-50,000
Closed -$1.01M
RARE icon
112
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-75,000
Closed -$1.73M
RCUS icon
113
Arcus Biosciences
RCUS
$3.44B
– –
-300,000
Closed -$7.15M
SMMT icon
114
PUT
Summit Therapeutics
SMMT
$10.7B
– –
-350,000
Closed -$6.12M
TNGX icon
115
Tango Therapeutics
TNGX
$4.65B
– –
-1,000,000
Closed -$8.86M
VTYX
116
DELISTED
Ventyx Biosciences
VTYX
– –
-6,484,558
Closed -$58.6M
XBI icon
117
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-1,500,000
Closed -$183M
XLV icon
118
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$41.4B
– –
-250,000
Closed -$38.7M
LENZ
119
PUT
LENZ Therapeutics
LENZ
$162M
– –
-100,000
Closed -$1.6M
PCSC
120
Perceptive Capital Solutions
PCSC
$123M
– –
-50,000
Closed -$652K
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Affinity Asset Advisors held 123 positions worth $1.94B, up 10% from $1.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors's Q1 2026 filing shows 29 new, 30 increased, 25 reduced and 18 closed positions. Its largest new stake was Enliven Therapeutics: 586,904 shares worth $23M. The largest sale was Ventyx Biosciences, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 77% a quarter earlier, followed by Financials.

  • Affinity Asset Advisors's largest Q1 2026 buy was Enliven Therapeutics: 586,904 shares worth $23M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q1 2026, an estimated $28.3M increase.
  • Affinity Asset Advisors's biggest Q1 2026 reduction was Wave Life Sciences, cutting an estimated $16.9M.
  • Affinity Asset Advisors fully exited Ventyx Biosciences in Q1 2026, selling an estimated $58.6M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.94B portfolio in Q1 2026.
  • Affinity Asset Advisors opened 29 new positions and closed 18 in Q1 2026.
  • Affinity Asset Advisors's portfolio value rose 10% quarter-over-quarter to $1.94B.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.